FDA’s Stem Cell Oversight Faces Pivotal Test In DC Circ. – Law360 (subscription)
|
FDA’s Stem Cell Oversight Faces Pivotal Test In DC Circ.
Law360 (subscription) Law360, New York (October 22, 2013, 8:46 PM ET) — The D.C. Circuit is poised to shape the future of stem cell therapy as it mulls the extent of the U.S. Food and Drug Administration’s power to regulate the potentially revolutionary field, likely … |
